VanEck Biotech ETF (NASDAQ:BBH) Major Shareholder Sardar Biglari Sells 2,749 Shares of Stock

VanEck Biotech ETF (NASDAQ:BBH) major shareholder Sardar Biglari sold 2,749 shares of the firm’s stock in a transaction on Thursday, July 16th. The shares were sold at an average price of $16.70, for a total transaction of $45,908.30. Following the completion of the transaction, the insider directly owned 3,549,961 shares in the company, valued at $59,284,348.70. This trade represents a 0.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Sardar Biglari also recently made the following trade(s):

• On Wednesday, July 15th, Sardar Biglari sold 6,533 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.71, for a total transaction of $109,166.43.
• On Tuesday, July 14th, Sardar Biglari sold 1,211 shares of VanEck Biotech ETF stock. The stock was sold at an average price of $16.73, for a total transaction of $20,260.03.

VanEck Biotech ETF Stock Performance

BBH opened at $206.25 on Friday. VanEck Biotech ETF has a fifty-two week low of $154.75 and a fifty-two week high of $212.54. The company’s 50-day moving average is $192.67 and its 200 day moving average is $191.86.

Institutional Trading of VanEck Biotech ETF

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BBH. Jane Street Group LLC bought a new position in shares of VanEck Biotech ETF in the first quarter valued at approximately $659,000. Raymond James Financial Inc. grew its holdings in VanEck Biotech ETF by 245.9% during the second quarter. Raymond James Financial Inc. now owns 67,940 shares of the company’s stock worth $10,414,000 after buying an additional 48,297 shares in the last quarter. Bank of America Corp DE grew its holdings in VanEck Biotech ETF by 17.7% during the second quarter. Bank of America Corp DE now owns 52,466 shares of the company’s stock worth $8,042,000 after buying an additional 7,898 shares in the last quarter. Corient Private Wealth LLC raised its position in VanEck Biotech ETF by 63.5% in the 2nd quarter. Corient Private Wealth LLC now owns 13,290 shares of the company’s stock valued at $2,037,000 after buying an additional 5,160 shares during the last quarter. Finally, Osaic Holdings Inc. raised its position in VanEck Biotech ETF by 87.1% in the 2nd quarter. Osaic Holdings Inc. now owns 1,465 shares of the company’s stock valued at $225,000 after buying an additional 682 shares during the last quarter. 32.05% of the stock is owned by institutional investors.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.